6.2. Risks in Immunocompromised Vaccinated PeopleĀ 
The vaccines that are currently available have either not been tested in immunocompromised individuals during phase 3 trials, or there is very limited information about such cases. As per CDC (Centres for Disease Control and Prevention) guidelines, immunocompromised patients involve patients with solid tumor and hematologic malignancies, solid organ transplant, hematopoietic stem cell transplant, moderate or primary immunodeficiency, and patients receiving high dose corticosteroids, chemotherapy, and immunosuppressants. Immunocompromised people are at a higher risk of experiencing severe COVID-19 symptoms and even after receiving a vaccination, they might not achieve the same level of protection from the infection as immunocompetent people. There are increasing concerns that in patients who have received an organ transplant and are thus immunocompromised due to the immunosuppressants administered to them, allograft rejection could occur following the administration of COVID-19 vaccination due to the sudden increase in the immune response that can act against the allograft. For patients who are administered immune checkpoint inhibitors, there is a risk of immune-related adverse effects due to unintentional activation of the immune system following the vaccination .In addition, patients who have undergone hematopoietic stem cell transplants represent a tricky group of people because administering the vaccine to them essentially requires the health care provider to balance the risk of a severe COVID-19 infection due to an immunocompromised state against the chances of a poor vaccine response. Inactivated vaccines are recommended and live vaccines are generally not advised and the consequences depend on the type of vaccine, age of the patient, and the time of the infection. Therefore, it is important to plan the vaccination of immunosuppressed patients to avoid drastic consequences and to maximize seroprotection.